LLY

Business Context and Reporting Period

This summary covers the Form 10-Q filed by Eli Lilly & Co for the quarter ended March 31, 2003. The company operates primarily in the pharmaceutical products segment, with a non-material animal health business. The reporting period reflects strong sales growth in key therapeutic areas, offset significantly by substantial one-time charges related to asset impairments, restructuring, and a failed drug development partnership.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 13% year-over-year, driven by a 7% volume increase, 4% favorable foreign exchange impact, and 2% price increase. Key growth drivers included Zyprexa (+17%), Humalog (+40%), Actos (+80% service revenue), and the launch of Strattera ($55.0 million).
• Profitability Decline: Net income decreased 35% and EPS decreased 34%. This decline was primarily due to $353.9 million in "Asset impairments, restructuring, and other special charges," a category that was zero in the prior year.
• Expense Increases: Marketing and administrative expenses rose 18% due to new product launches and litigation costs. R&D expenses increased 5% to $529.6 million.
• Debt Structure: Total debt increased slightly. The company issued $500 million in new long-term notes (2.9% 5-year and 4.5% 15-year) to refinance maturing debt.

Guidance, Outlook, and Risks

Management Commentary and Unusual Items

The significant drop in earnings was driven by three specific non-recurring charges totaling $353.9 million:

• Isis Pharmaceuticals Impairment ($186.8 million): Following negative Phase III trial results for the lung cancer drug Affinitak, the company wrote down its investment in Isis stock ($55.0 million), reserved against loans ($92.9 million), and recognized supply agreement charges ($38.9 million).
• Asset Impairments ($114.6 million): Charges related to the impairment of manufacturing assets in the U.S. following a strategic review.
• Restructuring ($52.5 million): Severance costs associated with eliminating approximately 700 positions to streamline infrastructure.

Guidance and Outlook

• Q2 2003 EPS: Excluding unusual items, management expects earnings per share in the range of $0.59 to $0.61.
• Full Year 2003 EPS: Including the Q1 charges of $0.23 per share, the company expects full-year EPS between $2.27 and $2.37, excluding future unusual items.
• Product Pipeline: Cymbalta approval is expected in Q4 2003. Cialis approval is anticipated in the second half of 2003. Forteo (Forsteo) European approval is expected in the second half of 2003.

Risks and Contingencies

• Patent Litigation: Ongoing lawsuits regarding generic challenges to Zyprexa (trial scheduled Jan 2004) and Evista (trial scheduled Feb 2005). An unfavorable outcome could materially impact operations.
• Product Liability: Numerous lawsuits involving Zyprexa, DES, and thimerosal. The company has accrued for estimated exposure.
• Regulatory Compliance: The FDA issued a warning letter regarding cGMP adherence at Indianapolis facilities. Reinspections are underway; failure to correct deficiencies could lead to production interruptions.

Investor Verification Checklist

• Verify the timeline and status of FDA reinspections for Indianapolis facilities and potential impact on Zyprexa and Cymbalta production.
• Monitor the progress of patent litigation regarding Zyprexa and Evista, specifically the scheduled trial dates in 2004 and 2005.
• Assess the commercial uptake of Strattera and Cialis post-launch to validate the revenue growth assumptions in the full-year guidance.
• Review the company's ability to maintain gross margins amidst rising manufacturing costs and quality improvement initiatives.
• Confirm the status of the $1.14 billion remaining in the share repurchase program and the execution of the accelerated repurchase agreement.